As of Jun 27
| -1.90 / -4.19%|
The 18 analysts offering 12-month price forecasts for Novozymes A/S have a median target of 44.79, with a high estimate of 54.70 and a low estimate of 38.68. The median estimate represents a +3.21% increase from the last price of 43.40.
The current consensus among 18 polled investment analysts is to Hold stock in Novozymes A/S. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.